Breast Cancer Clinical Trials
Breast Cancer
Learn More About Breast Cancer
For general information on breast cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | ClinicalTrials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| PTT-4256-01 | Breast Cancer | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256 | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| DM002001 | Breast Cancer | A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | NCT06751329 | Enquire Now |
| SR-8541A-001 | Breast Cancer | Phase 1, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of SR-8541A (ENPP1 Inhibitor) Administered Orally as Monotherapy or in Combination With Checkpoint Inhibitors in Subjects With Advanced/Metastatic Solid Tumors | Targeted | ENPP1 inhibitor | Open - Recruiting | Stingray Therapeutics | NCT06063681 | Enquire Now |
| SRG-514-01 | Breast Cancer | A Phase 1 Study of SRG-514 Administered Intraoperatively to the Site of Tumor Resection of Patients Undergoing Breast-Conserving Cancer Surgery | NSAID Gel | Intraoperative administration into breast cavity. Newly diagnosed BCa patients. Gel Ketorolac (NSAID by blocking cyclooxygenase (COX) enzymes). | Open - Recruiting | SURGE Therapeutics | NCT06300411 | Enquire Now |
| MTX-TROP2-302 | Breast Cancer | MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors | Immunotherapy | TROP2 targeting. Low volume disease only. | Closed | Myeloid Therapeutics | NCT05969041 | Enquire Now |
| ON-5001 | Breast Cancer | A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas | Injectable Lesion | Intratumoral (IT) injection. PC7A nanoparticles loaded with cGAMP. Stimulator of interferon genes. | Closed | OncoNano Medicine, Inc. | NCT06022029 | Enquire Now |